<?xml version="1.0" encoding="UTF-8"?>
<p>Treatment guidelines from China's National Health Commission included tocilizumab for patients with severe SARS-CoV-2 infection who also have increased IL-6 levels based on a multicenter, randomized controlled trial (
 <xref rid="B103" ref-type="bibr">103</xref>). Multiple IL-6 inhibitors including tocilizumab, sarilumab, and siltuximab are currently under investigation in clinical trials in China.
</p>
